Acetazolamide Per os for Decompensation of Heart Failure - Trial NCT05802849
Access comprehensive clinical trial information for NCT05802849 through Pure Global AI's free database. This Phase 4 trial is sponsored by Samara State Medical University and is currently Not yet recruiting. The study focuses on Chronic Heart Failure. Target enrollment is 400 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Samara State Medical University
Timeline & Enrollment
Phase 4
May 01, 2023
Sep 30, 2023
Primary Outcome
decrease of decompensation
Summary
The main causes of chronic heart failure (CHF) are arterial hypertension and coronary artery
 disease, less often cardiomyopathy, pericarditis, metastatic myocardial lesions. It should be
 noted that up to 50% of patients have a preserved left ventricular ejection fraction (LVEF),
 while its prevalence is progressively increasing annually.
 
 Acute decompensation of CHF is understood as a rapid increase in the severity of clinical
 manifestations (shortness of breath, severe arterial hypoxemia, the occurrence of arterial
 hypotension), which caused urgent medical treatment and emergency hospitalization in a
 patient already suffering from CHF. Decompensation of CHF requires intensification of
 treatment in order to stabilize the patient's condition. Strengthening diuretic therapy in
 addition to standard therapy helps to reduce edematous syndrome.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05802849
Non-Device Trial